STAAR Surgical Company (STAA) vs First Tracks Biotherapeutics Inc (TRAX)
A side-by-side comparison of STAAR Surgical Company and First Tracks Biotherapeutics Inc across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
STAA
STAAR Surgical Company
$22.15HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
TRAX
First Tracks Biotherapeutics Inc
$31.39HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — STAA vs TRAX
growth of $100 · dividends reinvested · last 1ySTAA +20.7% (+20.7%/yr)TRAX +73.6% (+73.6%/yr)TRAX compounded faster over this window
STAA TRAX
STAA vs TRAX: by the numbers
- •STAA is the larger company ($1.10B vs $1.10B market cap).
- •STAA is profitable (1.13% net margin) while TRAX runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | STAA | TRAX |
|---|---|---|
| P/E ratio | 276.87 | N/A |
| Forward P/E | 76.31 | N/A |
| P/S ratio | 3.25 | N/A |
| P/B ratio | 3.02 | 6.49 |
| EV / EBITDA | 22.47 | N/A |
Profitability
| Metric | STAA | TRAX |
|---|---|---|
| Gross margin | 76.23% | 0.00% |
| Operating margin | -19.19% | 0.00% |
| Net margin | 1.13% | 0.00% |
| ROE | 1.05% | -57.77% |
| ROIC | 4.80% | -59.76% |
Growth (annualized)
| Metric | STAA | TRAX |
|---|---|---|
| Revenue CAGR (5Y) | 10.49% | N/A |
| Total return CAGR (5Y) | -28.41% | N/A |
Frequently asked
- Is STAA or TRAX more profitable?
- STAA runs the higher net margin — STAA at 1.13% versus TRAX at 0.00%.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.